a therapeutically effective amount of a solid oral pharmaceutical dosage form of the present invention the invention also provides for the use of eltrombopag olamine in the manufacture of a solid oral pharmaceutical dosage form of the present invention the invention also provides for the use of eltrombopag olamine in the manufacture of a solid oral pharmaceutical dosage form of the present invention for use in enhancing platelet production the invention also provides for the use of eltrombopag olamine in the manufacture of a solid oral pharmaceutical dosage form of the present invention for use in treating thrombocytopenia the invention also provides for a solid oral pharmaceutical dosage form for use as a tpo mimetic which comprises eltrombopag olamine and a pharmaceutically acceptable carrier of the present invention the invention also provides for a solid oral pharmaceutical dosage form for use in the treatment of thrombocytopenia which comprises eltrombopag olamine and a pharmaceutically acceptable carrier of the present invention the invention also provides for a solid oral pharmaceutical dosage form for use in enhancing platelet production which comprises eltrombopag olamine and a pharmaceutically acceptable carrier of the present invention the invention also provides a process for preparing solid oral pharmaceutical dosage forms containing a diluent or diluents that are substantially free of coordinating metals and or that are substantially free of reducing sugars and a therapeutically effective amount of eltrombopag olamine which process comprises bringing eltrombopag olamine into association with the diluent or diluents no unacceptable toxicological effects are expected when the compound of the invention is administered in accordance with the present invention without further elaboration it is believed that one skilled in.